Interpace Biosciences Stock Performance
| IDXG Stock | USD 1.85 0.03 1.65% |
Interpace Biosciences holds a performance score of 14 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -2.38, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Interpace Biosciences are expected to decrease by larger amounts. On the other hand, during market turmoil, Interpace Biosciences is expected to outperform it. Use Interpace Biosciences potential upside, as well as the relationship between the kurtosis and day typical price , to analyze future returns on Interpace Biosciences.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Interpace Biosciences are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Interpace Biosciences reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 3.4 M | |
| Total Cashflows From Investing Activities | -315 K |
Interpace |
Interpace Biosciences Relative Risk vs. Return Landscape
If you would invest 86.00 in Interpace Biosciences on November 19, 2025 and sell it today you would earn a total of 99.00 from holding Interpace Biosciences or generate 115.12% return on investment over 90 days. Interpace Biosciences is currently generating 1.6719% in daily expected returns and assumes 9.3055% risk (volatility on return distribution) over the 90 days horizon. In different words, 83% of otc stocks are less volatile than Interpace, and 67% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Interpace Biosciences Target Price Odds to finish over Current Price
The tendency of Interpace OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.85 | 90 days | 1.85 | about 5.29 |
Based on a normal probability distribution, the odds of Interpace Biosciences to move above the current price in 90 days from now is about 5.29 (This Interpace Biosciences probability density function shows the probability of Interpace OTC Stock to fall within a particular range of prices over 90 days) .
Interpace Biosciences Price Density |
| Price |
Predictive Modules for Interpace Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Interpace Biosciences. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Interpace Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Interpace Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Interpace Biosciences is not an exception. The market had few large corrections towards the Interpace Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Interpace Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Interpace Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.49 | |
β | Beta against Dow Jones | -2.38 | |
σ | Overall volatility | 0.34 | |
Ir | Information ratio | 0.14 |
Interpace Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Interpace Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Interpace Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Interpace Biosciences is way too risky over 90 days horizon | |
| Interpace Biosciences may become a speculative penny stock | |
| Interpace Biosciences appears to be risky and price may revert if volatility continues | |
| Interpace Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Interpace Biosciences currently holds 9.44 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 41.31 M. Net Loss for the year was (14.94 M) with profit before overhead, payroll, taxes, and interest of 17.95 M. | |
| Interpace Biosciences currently holds about 1.86 M in cash with (8.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Roughly 28.0% of Interpace Biosciences shares are held by company insiders |
Interpace Biosciences Fundamentals Growth
Interpace OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Interpace Biosciences, and Interpace Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Interpace OTC Stock performance.
| Return On Equity | -2.85 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (0.59) % | |||
| Operating Margin | (0.28) % | |||
| Current Valuation | 11.72 M | |||
| Shares Outstanding | 4.27 M | |||
| Price To Earning | (1.07) X | |||
| Price To Book | 10.04 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 41.31 M | |||
| EBITDA | (9.12 M) | |||
| Cash And Equivalents | 1.86 M | |||
| Cash Per Share | 0.44 X | |||
| Total Debt | 9.44 M | |||
| Debt To Equity | 6.55 % | |||
| Book Value Per Share | (14.51) X | |||
| Cash Flow From Operations | (8.72 M) | |||
| Earnings Per Share | (3.12) X | |||
| Total Asset | 38.43 M | |||
| Retained Earnings | (172.59 M) | |||
| Current Asset | 19.16 M | |||
| Current Liabilities | 23.37 M | |||
About Interpace Biosciences Performance
By analyzing Interpace Biosciences' fundamental ratios, stakeholders can gain valuable insights into Interpace Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Interpace Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Interpace Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.Things to note about Interpace Biosciences performance evaluation
Checking the ongoing alerts about Interpace Biosciences for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Interpace Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Interpace Biosciences is way too risky over 90 days horizon | |
| Interpace Biosciences may become a speculative penny stock | |
| Interpace Biosciences appears to be risky and price may revert if volatility continues | |
| Interpace Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Interpace Biosciences currently holds 9.44 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 41.31 M. Net Loss for the year was (14.94 M) with profit before overhead, payroll, taxes, and interest of 17.95 M. | |
| Interpace Biosciences currently holds about 1.86 M in cash with (8.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Roughly 28.0% of Interpace Biosciences shares are held by company insiders |
- Analyzing Interpace Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Interpace Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Interpace Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Interpace Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Interpace Biosciences' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Interpace Biosciences' otc stock. These opinions can provide insight into Interpace Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Interpace OTC Stock analysis
When running Interpace Biosciences' price analysis, check to measure Interpace Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpace Biosciences is operating at the current time. Most of Interpace Biosciences' value examination focuses on studying past and present price action to predict the probability of Interpace Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Interpace Biosciences' price. Additionally, you may evaluate how the addition of Interpace Biosciences to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |